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Immunotherapeutic restoration in 
HIV-infected individuals
Current combined antiretroviral therapies 
(cARTs) attempt to minimize adverse drug 
events, such as long-term complications, and to 
circumvent drug resistance. The development of 
single-tablet, fixed-dose, combination antiretro-
viral drugs was intended to improve long-term 
compliance to cART. While the introduction 
of cART has dramatically improved life expec-
tancies and quality of life in HIV-1-infected 
individuals, clinical problems, including vari-
ous metabolic complications and HIV-associated 
neurocognitive disorder (HAND), have emerged 
as important constraints on life-long cART [1]. 
In addition, immune reconstitution by cART 
alone can be only partial and heterogeneous, 
although successful virologic suppression is 
achieved [2–5]. In addition, cART may result in 
the recovery of peripheral net CD4+ T lympho-
cytes, but it could not affect the reservoir of 
HIV-infected cells [5]. Furthermore, cART does 
not induce HIV-specific immune responses 
and HIV-specific immunity decreases during 
cART. For these reasons, alternative adjunctive 
immuno therapeutic strategies that complement 
cART remain active research foci. 
The depletion and immunologic dysfunc-
tion of T lymphocytes in HIV-infected indi-
viduals may result from loss of homeostasis, 
chronic immune activation by the HIV infec-
tion itself or bystander T lymphocyte death by 
other latent infections [6]. Cytokines that are 
important in the proliferation, function and 
regulation of T lymphocytes include IL-2, -7, -15 
and -21. However, impaired regulation of cyto-
kine production in HIV-infected individuals, 
which results in decreases of IL-2 or IL-15 and 
increases in TNF-a or IFN-g, may contribute to 
T lympho cyte dysfunction as well as a defective 
immune response [2]. 
Immunotherapy in HIV-infected individuals 
directly targets the aberrant immune response 
caused by HIV infection [3]. cART alone can-
not completely eliminate noncirculating infected 
cells and may not restore immunologic health 
in HIV-infected individuals [7]. Ongoing HIV 
replica tion results in immune activation, not 
only in individuals without treatment, but 
also during viral load (VL) suppression with 
cART [7,8]. In particular, immunologic low or 
nonresponders, defined as patients who have 
suboptimal immune restoration despite com-
plete control of HIV replication by cART, rep-
resent 5–30% of HIV-infected patients receiv-
ing cART [9]. The risk of disease progression or 
death is significantly higher in nonresponders 
compared with patients who achieve better 
CD4+ T lymphocyte restoration [9]. 
Because viral reservoirs in latently infected 
cells quickly start producing HIV particles when 
cART is discontinued, the control of viral reser-
voirs is very important for the eradication of 
HIV in humans. These problems have strength-
ened the rationale that new adjuvant immuno-
therapeutic restoration for the treatment of 
HIV-infected individuals must be explored. 
The development of new immunotherapeutic 
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strategies for the treatment of HIV infec-
tion is critical, especially for immuno logic 
non responders to cART and for use in sup-
portive adjuvants for structured treatment 
interruption (STI) of cART for antiretroviral 
drug conservation.
In this article, we reviewed up-to-date 
knowledge regarding various clinical aspects 
of immuno therapy in HIV-infected individu-
als. Figure 1 summarizes important research 
trajectories outlined in this article. 
Cytokine immunotherapy 
 n IL-2
IL-2 is a cytokine that is produced by activated 
T lymphocytes and that regulates the growth, 
differentiation, survival and death of multiple 
lymphocyte subsets, particularly CD4+ and 
CD8+ T lymphocytes [10]. IL-2 enhances cyto-
lytic activity against a number of target cells and 
improves the function of natural killer (NK) 
cells [10,11]. HIV infection is characterized by 
deficiencies in IL-2 caused by the progressive 
destruction and functional impairment of CD4+ 
T lymphocytes [12]. Administration of IL-2 to 
HIV-infected patients leads to expansion of 
lymphocytes through prolongation of lympho-
cyte half-lifes, along with increases in naive 
and central memory cells, and a concomitant 
decrease in the level of HIV-associated immune 
activation [13,14].
Since 1995, numerous Phase II, randomized, 
controlled clinical trials have tested the effects 
of Escherichia coli-expressed and human recom-
binant IL-2 (hrIL-2) in small samples of HIV-
infected individuals at various stages of HIV 
infection. These studies demonstrated that intra-
venous or subcutaneous hrIL-2 administration, 
combined with ART, may result in significant 
increases in CD4+ T lymphocyte counts com-
pared with the effects of cART alone [15–21]. The 
following findings were also established: 
  Patients tolerate subcutaneous administration 
of IL-2 better than continuous intravenous 
injection, although both administration routes 
demonstrate similar efficacy [22]; 
  Polyethylene glycol (PEG) hrIL-2 exhibits 
decreased biologic efficacy [22,23]; 
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Figure 1. Immunotherapeutic approaches to primary or adjuvant therapy in HIV infection. 
Ab: Antibody; ART: Antiretroviral therapy; AV-HALT: Antiviral hyperactivation-limiting therapeutic; 
cART: Combined antiretroviral therapy; GcMAF: Gc protein-derived macrophage-activating factor; 
mAb: Monoclonal antibody; STI: Structured treatment interruption.
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  Once-daily doses of 3 million IU of sub-
cutaneous hrIL-2 lead to stable increases in 
CD4+ T lymphocyte counts and are better 
tolerated by patients [24–26] as are twice daily 
injections of 4.5 million IU, which lead to 
equal efficacy and fewer toxic reactions [16,27–29];
  5-day cycles of intravenous hrIL-2 adminis-
tered every 8 weeks are more effective for 
increasing CD4+ T lymphocyte counts than 
longer and more frequent schedules [21,30];
  The magnitude of CD4+ T lymphocyte expan-
sion is associated with the dose of subcutaneous 
or intravenous hrIL-2, baseline or nadir CD4+ 
T lymphocyte counts and plasma HIV VL. 
Absolute increases in CD4+ T lymphocytes are 
greater in patients with higher baseline CD4+ 
T lymphocyte counts [15,17,20,25,31]. 
The clinical benefits of subcutaneous hrIL-2 
therapy were most recently evaluated in two of 
the largest prospective, randomized, controlled, 
Phase III, multicenter studies; the Multicenter 
Randomized Study of the Biological and Clinical 
Efficacy of Subcutaneous Recombinant, Human 
Inteleukin-2 in HIV-Infected Patients with 
Low CD4 Counts under Active Antiretroviral 
Therapy (SILCAAT), and the Evaluation of 
Subcutaneous Proleukin in a Randomized 
International Trial (ESPRIT) [32]. The main 
aims of these studies were to determine the clini-
cal end point of hrIL-2 therapy, which includes the 
occurrence of opportunistic infection and death, 
and to evaluate the safety of hrIL-2 therapy [32]. 
Table 1 summarizes the most important character-
istics and results of these two trials. The patient 
samples in the SILCAAT and ESPRIT studies 
included HIV-1 infected adults with low (50–299 
cell/mm3) and high CD4+ T lympho cyte counts 
(more than 300 cells/mm3), respectively [32]. Both 
studies randomized subjects into two groups of 
equal numbers to receive either hrIL-2 plus cART 
or cART alone [32]. The results of SILCAAT and 
ESPRIT were discouraging, owing to the fact that 
the combination of hrIL-2 with cART yielded no 
clinical benefits. The primary end point, either 
the development of opportunistic disease or death 
from any cause, occurred at similar stages in 
patients treated with a combination of hrIL-2 as in 
patients treated with cART alone, despite substan-
tial and sustained increases in CD4+ T-lymphocyte 
counts in the former group, especially during the 
early stages of IL-2 administration [32].
Furthermore, many studies have revealed that 
intermittent subcutaneous hrIL-2 can gener-
ate various side effects, ranging from minor 
gastrointestinal symptoms, fever, myalgia, fatigue 
and hyperbilirubinemia, to serious symptoms 
such as psychological disorder or vascular events 
(such as capillary leakage, shock, myocardial 
infarction and deep vein thrombosis) [32–38]. 
 n IL-7
IL-7 is a principal homeostatic cytokine for 
T lymphocytes, and is critical for the main-
tenance of CD4+ and CD8+ naive T lympho-
cytes [39]. In an animal study, IL-7 administration 
altered peripheral T lymphocyte homeostasis 
in both normal and simian immunodeficiency 
virus (SIV)-infected nonhuman primates and 
induced immunological improvement in SIV-
infected rhesus macaques that were being treated 
with an antiviral therapy [40,41]. Therefore, IL-7 
therapy may lead to the expansion of CD4+ and 
CD8+ T lymphocyte reservoirs in patients with 
lymphocyte depletion [39,42–44]. T lymphocyte 
expansion also results in a significant broadening 
of circulating T-cell receptor (TCR) repertoire 
diversity [45]. In a small, nonrandomized, human 
study, human recombinant IL-7 (hrIL-7) was 
administered subcutaneously in 16 patients with 
refractory cancer [45]. Both CD4+ and CD8+ 
T lymphocyte counts increased, suggesting 
that hrIL-7 therapy may enhance and broaden 
immune response, particularly in patients with 
limited naive T lymphocytes and decreased 
TCR repertoire diversity, such as HIV-infected 
patients [45].
CYT 99 007, a first-generation nonglyco-
sylated form of hrIL-7, was evaluated in pre-
clinical and Phase I studies of HIV-infected 
individuals and found to be well tolerated in 
repeated dose trials. Administration of CYT 
99 007 also triggered long-lasting increases in 
both CD4+ and CD8+ T lymphocytes [46]. A 
second- generation glycosylated hrIL-7, CYT 
107, was evaluated in the Investigational Study of 
Placebo versus IL-7 in HAART-Treated Patients 
(INSPIRE) study, a Phase I/IIa, randomized, 
placebo controlled, single-blind, multi center 
trial of chronic HIV-infected individuals with 
CD4+ T lymphocyte counts between 101 and 
400 cell/mm3 and plasma HIV VL fewer than 
50 copies/ml follow ing 12 months of cART. 
Three different test dose amounts (10, 20 or 
30 µg/kg/week) of CYT 107 were adminis-
tered subcutaneously thrice weekly in a sample 
of eight patients, with two additional control 
patients receiving placebo. Based on an interim 
analysis that was presented in 2009, three 
cycles of CYT 107 induced a sustained, dose-
dependent increase of CD4+ T lympho cytes [47]. 
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A higher proportion of patients demon strated 
CD4+ T lymphocyte counts that were higher 
than 500 cells/mm3. Patients receiving injec-
tions of 20 µg/kg/week demonstrated a trend 
towards higher thymic output as well as median 
increases of CD4+ and CD8+ T lymphocyte 
counts from 240 to 563 cells/mm3 (135%) and 
from 659 to 1210 cells/mm3 (65%), respectively. 
All patients tolerated the treatment well, with-
out clinical or laboratory toxicities rated higher 
than grade 2. However, it remains unclear as to 
whether the immunologic restoration achieved 
by hrIL-7 therapy is correlated with improved 
clinical outcomes such as decreases in mor-
bidity and mortality, or whether increases in 
CD4+ T lymphocytes continue over the long 
term, especially in immunologic nonresponders 
compared with patients who exhibit higher 
CD4+ T lympho cyte counts following cART. 
These questions should be addressed by large, 
well-designed clinical studies.
 n IL-21
IL-21 was relatively recently discovered to be a 
significant, multifunctional, immune- enhancing 
and immune-regulatory cytokine and several 
in vivo animal model studies have revealed that 
IL-21 plays an essential role in controlling chronic 
viral infections [48–50]. IL-21 can also promote 
differentiation of naive CD4+ T lymphocytes 
into IL-17-producing CD4+ T lymphocytes 
(Th17 cells), which play an important role in 
inducing inflammation and controlling invading 
pathogens [51,52]. CD4+ T lymphocytes are the 
main producers of IL-21 in humans [53]. IL-21, 
unlike IL-2, does not support proliferation of 
anti-CD3-activated regulatory T cells that are 
involved in the suppression of antiviral immu-
nity [54]. Serum levels of IL-21 were significantly 
decreased in chronic HIV-infected individuals 
and were correlated with CD4+ T lymphocyte 
counts [55,56]. Recently, Iannello et al. reported 
that IL-21 production was compromised early in 
the course of HIV infection, and maintained nor-
mally in only elite controllers [56]. This study also 
revealed that cART alone partially restored the 
produc tion of IL-21 and the frequencies of IL-21-
producing HIV-specific antigen- experienced 
CD4+ T lymphocytes were decreased in HIV-
infected patients [56]. Furthermore, recombinant 
human IL-21 prevented enhanced spontaneous 
ex vivo death of CD4+ T lymphocytes from 
HIV-infected individuals [56]. These findings 
suggest that IL-21 should be considered for 
immunotherapy in HIV-infected individuals.
Gc protein-derived 
macrophage-activating factor
Serum Gc protein, also known as vita-
min D3-binding protein, is the precursor of 
macrophage-activating factor (MAF). In HIV-
infected individuals, MAF precursor activity of 
Table 1. Summaries of the SILCAAT and ESPRIT studies of IL-2 therapy in patients with HIV infection. 
Important issues SILCAAT (n = 1695) ESPRIT (n = 4111)
Characteristics of study 
participants
Low CD4+ T-cell count (50–299/mm3) 
and plasma HIV-RNA ≤10,000 copies/ml
IL-2 combined with cART: 849 patients
IL-2 alone: 846 patients
High CD4+ T-cell count ≥300/mm3
IL-2 combined with cART: 2071 patients
IL-2 alone: 2040 patients
Schedule of IL-2 administration Induction phase (within 12 months)
1. One cycle (9 million IU/day, every 12 h, for 
5 consecutive days)
2. Six cycles, approximately 8 weeks apart
Maintenance phase
Induction phase (within 12 months)
1. One cycle (15 million IU/day, every 12 h, for 
5 consecutive days)
2. Three cycles, approximately 8 weeks apart
Maintenance phase
CD4+ T lymphocyte counts 
(median increase in IL-2 combined 
with cART compared with 
cART alone according to 
follow-up duration)
1 year: 99/mm3
6 years: 38/mm3
On average: 53/mm3 (95% CI: 40–66)
1 year: 185/mm3
6 year: 113/mm3
On average: 159/mm3 (95% CI: 145–174)
Primary end point: opportunistic
disease or death from any cause
IL-2 combined with cART: 110 (1.94)
cART alone: 119 (2.13)
HR with IL-2, 0.91 (95% CI: 0.70–1.18); p = 0.47
IL-2 combined with cART: 159 (1.14)
cART alone: 165 (1.21)
HR with IL-2, 0.94 (95% CI: 0.75–1.16); p = 0.55
Grade 4 adverse events IL-2 combined with cART: 203 (3.93)
cART alone: 186 (3.58)
HR with IL-2, 1.10 (95% CI: 0.90–1.34); p = 0.35
IL-2 combined with cART: 466 (3.80)
cART alone: 383 (3.09)
HR with IL-2, 1.23 (95% CI: 1.07–1.41); p = 0.003
Data are presented as number of patients (rate/100 person-year). 
cART: Combined antiretroviral therapy; ESPRIT: Evaluation of Subcutaneous Proleukin in a Randomized International Trial; HR: Hazard ratio; IU: International unit; 
SILCAAT: Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human IL-2 in HIV-Infected Patients with Low CD4 
Counts Under Active Antiretroviral Therapy.  
Adapted from [32].
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the serum Gc protein is lost or reduced, because 
the Gc protein is deglycosylated by a-N-acetylga-
lactosaminidase that is released from the gp120 of 
HIV-infected lymphocytes [57,58]. This decrease 
in macrophage activation may result in immuno-
suppression [58,59]. Therefore, the administration 
of Gc protein-derived macrophage- activating fac-
tor (GcMAF) may effect immune restoration in 
HIV-infected individuals. A small, nonrandom-
ized, clinical study performed in 15 asymptom-
atic treatment-naive Japanese HIV-infected indi-
viduals was reported in 2009 [57]. Throughout 
the 7-year study period, less than 18 weekly intra-
muscular injections of 100 ng GcMAF led to 
recovery of low serum a-N-acetylgalactosamin-
idase activities that were equivalent to those of 
non-HIV-infected controls and the maintenance 
of CD4+ T lymphocyte counts that were within 
the normal range (798 ± 213 cells/mm3). Plasma 
HIV VL and p24 antigen levels also decreased 
follow ing GcMAF therapy owing to immuno-
logic restoration [57]. Interestingly, the cessation 
of GcMAF therapy did not result in rebounds 
of serum a-N-acetylgalactosaminidase activities, 
HIV VL or p24 antigen levels [57]. 
Therapeutic immunization 
The concept of therapeutic immunization 
for HIV-1 infection was first raised by Salk 
in 1987 [60]. The main purpose of therapeutic 
immunization is to immunize for the induction of 
HIV-antigen-specific immune response in already 
HIV-infected individuals, paricularly T-cell 
immunity that may maintain immunologic con-
trol capacity in HIV infection [61]. Therapeutic 
immunization has several potential indications 
that complement cART. For example, it may sus-
tain immunologic fitness or HIV control during 
the early period of HIV infection so that the ini-
tiation of cART can safely be delayed, as well as 
the safe cART-free periods can be prolonged in 
chronic asymptomatic HIV-infected individu-
als. Moreover, therapeutic immunization may 
maintain HIV control and immunologic fitness 
in HIV-infected patients receiving continuous 
cART, especially patients who fail to restore or 
maintain adequate CD4+ T lymphocyte counts. 
cART, combined with therapeutic immuniza-
tion, must be able to suppress HIV bursts arising 
from HIV-1-infected CD4+ T lymphocytes that 
are activated by immunization [62]. 
Therapeutic immunization can, theoretically, 
induce HIV-specific polyfunctional CD4+ and 
CD8+ T lymphocyte immune response and, 
therefore, control HIV replication [61]. However, 
several candidate HIV vaccines (subunit or 
whole inactivated virus) have proven ineffective 
for controlling HIV replication. These findings 
have prompted new investigations evaluating the 
potential of therapeutic immunization. 
Newer approaches utilize common, effec-
tive g-chain cytokine adjuvants as immuno-
modulators to enhance vaccine-induced 
HIV-specific, adaptive immune responses. In 
particular, HIV-infected patients with discordant 
responses to cART, such as plasma HIV VL that 
become fully suppressed while CD4+ T lympho-
cyte counts remain suboptimal, may become 
important candidates for restorative therapeutic 
immunization with immunomodulators. These 
strategies for replenishing destroyed CD4+ mem-
ory T lymphocyte populations and augmenting 
vaccine-induced specific immunities have focused 
on the roles of cytokines that are part of the com-
mon g-chain cytokine family (such as IL-2, -7, -12 
and -15), which regulate proliferation, activation, 
differentiation and survival of T lymphocytes. 
The SIV infection model in rhesus macaques 
has been used to evaluate the effectiveness of 
immuno modulator cytokines as therapeutic 
vaccine adjuvants. Several animal studies have 
revealed that IL-2 and IL-15 adjuvant vaccines 
preserve peripheral CD4+ T lymphocyte counts 
and decrease the VL set point [63–67]. However, 
in order to determine the true efficacies of these 
cytokines as therapeutic vaccine immunomodu-
lating adjuvants, human trials must be performed 
in various c linical settings. 
Dendritic cell (DC)-based HIV vaccine strat-
egies have recently been investigated [3,68–71]. 
DCs of myeloid origin are the most potent 
professional antigen-presenting cells (APCs) in 
HIV infection [3]. In particular, myeloid DCs 
have the exceptional ability to activate T-cell 
immune responses to HIV, which is why these 
cells have been explored as ex vivo and in vivo 
immunotherapies [72,73]. The use of DCs for 
HIV immunotherapy effectively controls HIV 
replication by using natural pathways of antigen 
recognition and processing during HIV-specific 
immune response. Such therapies could prolong 
the length of the healthy cART period. Myeloid 
DCs may be grown from blood monocytes by 
culturing in IL-4 and GM-CSF, a breakthrough 
that may clear the method for ex vivo immuno-
therapeutic human trials [74,75]. Several clinical 
trials have already tested DC-derived vaccines 
in small samples of HIV-infected patients. 
Immature autologous or allogenic blood DCs 
or IL-4/GM-CSF monocyte-derived DCs were 
generated using various adjuncts to promote 
DC maturation, including IL-1b/IL-6/TNF -a, 
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monocyte-conditioned medium, and TNF-a 
alone [72,76–80]. These studies have yielded prom-
ising results, including reduction of plasma HIV 
VL or maintenance of stable VL after STI [3]. 
 Because naturally occurring human anti-
bodies, developed by specific immune humoral 
responses to HIV infection, are unable to effi-
ciently neutralize HIV, clear the infection or pre-
vent disease progression, passive immunization 
with more potent appropriate neutralizing anti-
bodies for HIV may be a solution for immuno-
therapy in HIV-1-infected patients. Neutralizing 
antibodies against HIV-1 could result in anti-
HIV activity even in cART-experienced patients, 
and B lymphocytes can be stimulated to generate 
high titers of broadly cross-reactive neutralizing 
antibodies against multiple subtypes of HIV. 
 n Polyclonal anti-HIV IgG 
antibody (PEHRG214)
PEHRG214 is a polyclonal anti-HIV IgG antibody 
preparation produced by immunization of goats 
with purified HIV-associated proteins followed 
by booster immunizations with synthetic peptides 
to highly conserved HIV epitope regions without 
recognition by the human immune system [81,82]. 
PEHRG214 has a high titer and affinity to multiple 
unique epitope regions on HIV, including two on 
gp120 and one each on gp41, p24, p66, p17 and 
p11. It could potently neutralize and lyse a broad 
spectrum of primary and reference HIV isolates 
in vitro [83]. In a Phase I study, a single intra-
venously  administered dose of PEHRG214 was 
reasonably well tolerated and achieved adequate 
plasma concentrations, exceeding those found to 
neutralize HIV in laboratory experiments [81,82]. 
A HRG2 study (clinical trial NCT00385567) was 
performed as a Phase II, random ized, control-
led, open-label, multidose trial to determine the 
efficacy, safety, immunogenicity and pharmaco-
kinetic profiles of PEHRG214 in HIV-infected 
patients receiving optimized background regi-
men (OBR) of antiretroviral agents, treated intra-
venously three-times weekly for up to 16 weeks. 
The primary objective of this study was to deter-
mine the effect of PEHRG214 on decreasing the 
plasma VL, as compared with a control group. 
This study was commenced in January 2007, but 
has been terminated owing to the difficulty in 
recruiting eligible patients in a timely fashion [201].
 n The Thymon University  
Tat immunogen (TUTI-16)
HIV-1 Tat protein, a virally encoded toxin, is 
secreted by HIV-1-infected cells and acts on 
uninfected cells, making them permissive to 
HIV-1 replication. HIV-1 Tat enhances chronic 
HIV replication and induces immune suppres-
sion. HIV-1 Tat activities can be blocked in vitro 
and in vivo by anti-Tat antibodies. Antibodies to 
Tat inhibit Tat-mediated transcellular activation 
in vitro and minimize chronic plasma viremia. 
TUTI-16 is a fully synthetic, self-adjuvanting, 
lipopeptide vaccine that is water soluble and 
administered by subcutaneous injection. In a pre-
clinical study, a priming dose and a 3-week boost 
in rats induced a high-titer antibody response 
to the eight known distinct epitope variants of 
HIV-1 Tat protein. These antibodies blocked the 
function of the HIV-1 Tat protein (toxin), which 
is essential to the maintenance of chronic HIV-1 
viremia [84]. Therefore, TUTI-16 has potential as 
a therapeutic vaccine for HIV-1-infected individ-
uals. The Phase I/IIa clinical study of TUTI-16 
in asymptomatic HIV-1-infected and -uninfected 
subjects will be performed to gather safety and 
human immuno genecity (anti-HIV-1 Tat anti-
body titer) data on subcutaneously administrated 
TUTI-16 [201].
Monoclonal antibodies
 n Humanized anti-CD4 IgG 
monoclonal antibody (ibalizumab)
HIV-1 entry into host cells is a multistep pro-
cess that offers several potential targets for anti-
retroviral treatment. Ibalizumab, formerly called 
TNX-355 and Hu548, is a humanized anti-CD4 
IgG
4
 monoclonal antibody (mAb) of murine ori-
gin that interferes with HIV entry. Ibalizumab 
binds to the interface between domain 1 and 2 
of the extracellular region of CD4 [85]. It appears 
to result in anti-HIV activity due to postbinding 
conformational effects that prevent CD4-bound 
gp120 from interacting with CCR5 or CXCR4, 
instead of directly inhibiting the binding of gp120 
to CD4 [86]. Because ibalizumab binds a site away 
from the MHC class II molecule, it does not cause 
an immunosuppressive state, unlike other mAbs 
that target domain 1 of CD4 and competitively 
inhibit gp120 binding that can interfere with 
MHC class II immune function [87]. The average 
half-life of ibalizumab is 3–3.5 days shorter than 
the 2–3 weeks of IgG under normal physiological 
circumstances [88].
The first Phase I clinical study to determine 
the anti-HIV activity and safety of TNX-355 in 
30 HIV-infected individuals, who were not on 
cART or were on a failing regimen with a plasma 
HIV VL greater than 5000 copies/ml, was per-
formed with the administration of single-dose, 
intravenous infusions over five doses, ranging 
from 0.3 to 25 mg/kg. The dose-related reductions 
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in plasma HIV VL were observed in the 3, 10 and 
25 mg/kg groups. In addition, dose-dependent 
peak increases in CD4+ T lymphocytes were 
observed within 24 h of treatment. Nonserious 
adverse events did not cause the discontinuation 
of the treatment in any subjects [89].
A Phase Ib multidose study for evaluating the 
anti-HIV activity, pharmacokinetics and safety 
of ibalizumab in 22 HIV-infected patients, 
who remained off other antiretroviral drugs 
or continued a stable failing regimen, revealed 
that ibalizumab, intravenously administered 
either weekly or biweekly had anti-HIV activ-
ity, good tolerability and safety [88]. There was 
neither immunogenicity nor severe drug-related 
adverse events [88]. Treatment with ibalizumab 
resulted in substantial rapid peak reduction of 
plasma HIV VL (0.5–1.7 log
10
) in 20 out of 22 
patients following 1–2 weeks of treatment, and 
did not cause CD4+ T lymphocyte depletion [88]. 
Interestingly, an in vitro study revealed high level 
synergistic, anti-HIV activity when ibalizumab 
and the other entry inhibitor, enfuvirtide, were 
combined together [90]. In addition, in a Phase Ib 
study, there was no evidence of cross-resistance 
between the two entry inhibitors [88].
The 24-week analysis of a randomized, 
double-blinded, placebo-controlled, Phase IIa 
study was performed and presented [91]. A total 
of 82 antiretroviral triple classes-experienced 
patients were randomized to receive ibalizumab 
(10 mg/kg weekly for 8 weeks, followed by either 
10 mg/kg every 2 weeks, or 15 mg/kg every 
2 weeks, to complete 24 weeks) versus placebo 
in addition to an OBR. The plasma HIV VL 
reductions were significantly greater in the two 
treatment arms, with a mean 0.95 log
10
 decrease 
in the 15 mg/kg arm and 1.16 log
10
 decrease in 
the 10 mg/kg arm compared with a 0.20 log
10
 
decrease in the placebo arm.
Furthermore, ibalizumab administrated as 
an intravenous infusion, displayed promising 
anti-HIV activity and safety in early clinical 
trials [88,89]. Until now, the immuno suppressive 
effects had not been demonstrated with ibali-
zumab in nonhuman primates and human 
clinical trials [88,92].
 n Anti-V3 neutralizing mAb (KD-247)
 An antibody response capable of neutralizing 
not only the homologous, but also the hetero-
geneous, form of the CXCR4-tropic HIV-1 
MNp and CCR5-tropic (R5) HIV-1
JR-CSF
 was 
achieved through sequential immunization with 
a combination of synthetic peptides representing 
HIV-1 Env V3 sequences from HIV-1 clade B 
isolates [93]. The anti-V3 mAbs generated from 
peripheral blood mononuclear cells (PBMCs) of 
HIV-infected individuals have been shown to 
contain cross-neutralizing anti-V3 mAbs that 
neutralize primary HIV isolates [94,95]. Through 
the sequential immunization of mice with V3 
peptides from HIV-1 clade B field isolates, the 
cross-reactive antisera that strongly bound to 
V3 peptides from homologous and heterologous 
primary isolates was inducted [93]. 
KD-247 is a reshaped, humanized, anti-V3, 
neutralizing mAb, derived from a C25 gene 
that efficiently neutralized primary isolates of 
HIV-1 [93]. C25 was obtained by immunizing 
mice sequentially with six V3 peptides, repre-
senting clade B HIV-1 viruses [96]. KD-247 
was generated by transferring the genes of the 
complementary determining region of C25 into 
the genes of the human V region of the anti-
body [93,97]. The epitope of KD-247 was mapped 
to six amino acids, IGPGRA, at the tip of the 
gp120–V3 loop [93,98]. It bound with high affinity 
to the PGR motif within the HIV-1 Env V3 tip 
region, and displayed potent cross-neutralizing 
activity against subtype B, primary HIV-1 iso-
lates [93]. Among the established refer ence of anti-
V3 mAbs, KD-247 most effectively neutralized 
primary HIV-1 field isolates including R5 viruses 
possessing the matching neutralization sequence 
motif, suggesting its promise for clinical applica-
tions [93]. The complete protection from chal-
lenge of infection by a pathogenic simian/human 
immunodeficiency virus (SHIV) 89.6 strain was 
observed when a high concentration of KD-247 
was used in this animal model [99]. In addition, 
KD-247 might not only directly neutralize the 
HIV, but also maintain CD4+ T lymphocytes in 
lymphoid tissues [97]. Because KD-247 showed 
the complete, or strong, inhibition of HIV rep-
lication ex vivo and the protection of monkeys 
against the highly pathogenic simian/human 
immuno deficiency virus, KD-247 could be a 
promising new immunotherapeutic candidate 
for HIV-infected individuals [93,96,99]. 
 However, neutralization evasion from anti-V3 
mAbs, including KD-247, has been reported and 
associated with amino acid substitution mutation 
within the epitope of the V3 loop and outside V3 
including V2 region [95,98]. In addition, a clone 
with a V2 potential N-linked glycosylation site 
insertion and mutation in V3 demonstrated a 
high level of resistance to KD-247 [100]. Through 
the acquisition of a potential glycosylation site in 
V2, HIV can escape a neutralizing anti-V3 mAb. 
However, one study revealed that high concentra-
tions of KD-247 are needed for viral acquisition 
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of KD-247 resistance and that the escape vari-
ants are more sensitive to CCR5 inhibitors. In 
addition, there was a strong synergistic effect 
between KD-247 and CCR5 inhibitors at all 
concentrations tested [101].
 n CCR5 mAbs
CCR5 mAb binds to CCR5 and potently inhib-
its R5 HIV-1 in vitro. A few CCR5 mAbs have 
demonstrated broad and potent anti-HIV activity 
in vitro [102–104]. The most potent CCR5 mAbs 
showed an IC
50
 in the range of 0.1–1.0 µg/ml, 
with an approximately 1 log
10
 variation across 
diverse viral isolates. The mAbs resulted in essen-
tially complete inhibition of HIV replication at 
higher concentrations [105–107]. CCR5 mAbs have 
demonstrated similar potencies for HIV strains 
derived from various stages of disease [108], 
genetic subtypes [104,109,110] and pediatric/adult 
infection [111]. CCR5 mAbs efficiently inhib-
ited the CCR5-mediated entry of dual/mixed 
(R5X4) virus in cell lines that express CCR5 but 
not CXCR4 [104,111]. However, limited inhibi-
tion of R5X4 viruses was observed in cultures of 
PBMCs [108–110].
Two human CCR5 mAbs of IgG
4
 isotype, that 
is, PRO140 and HGS004, have recently entered 
clinical trials in HIV-infected individuals with 
only R5-virus detectable, plasma VL greater 
than 5000 copies/ml, CD4+ T lympho cytes 
greater than 250 cells/mm3 and no concurrent 
cART [112,113]. These studies have successfully 
completed proof-of-concept, providing initial 
information on the potential therapeutic util-
ity of these agents [112,113]. Clinical studies have 
established CCR5 mAbs as potent antiretroviral 
agents with prolonged activity following a single 
dose. Therefore, CCR5 mAbs can represent both 
a distinct class of CCR5 inhibitor and a novel 
approach to HIV-1 immunotherapy.
PRO140 is a humanized form of the mouse 
CCR5 mAb PA14 that binds an epitope span-
ning extracellular loop 2 (ECL2) and amino-
terminal domain and does not antagonize the 
natural activity of CCR5 in vitro [108,111,114]. 
The potency and breadth of anti-HIV activity 
for PA14 and PRO140 have been demonstrated 
in several preclinical studies [108,109,111,114]. The 
first clinical trial of PRO140 in HIV-infected 
individuals was a Phase I, randomized, double-
blind, placebo-controlled, dose-escalating study 
in 39 patients with early-stage infection, no 
cART for 3 months and only R5 HIV-1 detect-
able, to evaluate the pharmacokinetics, tolerabil-
ity, receptor occupancy and anti-HIV effects of 
single, escalating-doses infusion, ranging from 
0.5, 2 to 5 mg/kg [113]. In this trial, the single, 
intravenous infusion of PRO140 was gener-
ally well tolerated and no dose-limiting toxic-
ity was observed [113]. In addition, PRO140 
demon strated potent, rapid, prolonged and 
dose-dependent anti-HIV activity, and a highly-
significant reduction in mean VL of tenfold or 
more was observed within 4 days for each of 
the dosing groups and persisted for 2–3 weeks 
after treatment in the 5 mg/kg group [113]. 
In the 5 mg/kg PRO140 group, there was a 
trend towards increased CD4+ T lymphocytes 
over baseline, the significant CCR5 receptor 
occupancy was observed for 2–4 weeks in all 
PRO140 groups and there was no depletion of 
CCR5+ cells following treatment [113]. In another 
clinical trial of a similar design to that of the first 
studies, PRO140-administrated subcuta neously 
also offered the potential for significant and pro-
longed, dose-dependent, HIV-1 RNA suppres-
sion, and demonstrated good tolerability [115]. 
In the most recently reported Phase IIa study of 
PRO140, administrated intravenously, the mean 
maximum reduction from baseline HIV-1 RNA 
was 1.8 log
10
 for both 5 and 10 mg/kg doses 
(p < 0.001 control to placebo) [116]. VL nadired at 
day 12 postinfusion and remained significantly 
reduced through day 29 for both PRO140 dose 
groups (p < 0.01) [116]. Consequently, the single 
5 and 10 mg/kg intravenous treatments with 
PRO140 exhibited potent, long-lived anti-HIV 
activity and were generally well tolerated [116]. 
However, further studies in humans must be 
performed in various clinical settings, includ-
ing in patients receiving cART, or patients with 
treatment-experience or advance-stage infection. 
HGS004 (CCR5mAb004) is a human mAb 
that binds ECL2 and inhibits R5 HIV-1 entry 
and chemokine signaling with similar efficien-
cies to that of PRO140 [112,117]. The results of 
a Phase I, single-blind, randomized, placebo-
controlled clinical trial to evaluate the tolera-
bility, pharmacokinetics, receptor occupancy 
and anti-HIV effects of single, escalating 
doses, ranging from 0.4, 2, 8, 20 to 40 mg/kg 
HGS004 in 63 HIV-infected subjects, revealed 
that HGS004 was generally well tolerated and 
showed meaningful anti-HIV activity when 
administered to individuals with R5 HIV-1 tro-
pism [112]. Significant reductions in HIV-1 VL 
were observed at doses of 8 mg/kg and higher 
and the mean CCR5 receptor occupancy was 
approximately 80% at day 28 for each of the 
three highest dose groups [112]. In addition, sig-
nificant increases in CD4+ T lymphocyte counts 
were observed in all HGS004 dose groups [112]. 
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CCR5mAbs are distinctly different from 
small-molecule CCR5 antagonists (e.g., mara-
viroc, vicriviroc [SCH-417690], aplavi-
roc, TAK-220, TAK-779, SCH-350581 and 
SCH-351125 [SCH-C]) in terms of their sites 
or mechanisms for CCR5 binding and HIV-1 
inhibition. CCR5mAbs and small-molecule 
CCR5 antagonists can be considered distinct 
classes of CCR5 inhibitors based on their potent 
anti-HIV synergy and lack of cross-resistance. 
Despite demonstrating high-level resistance to 
the small-molecule CCR5 antagonists, HIV 
remains susceptible, or even hypersusceptible, 
to inhibition by CCR5mAbs [118–120]. In one 
study among HIV-infected subjects with treat-
ment failure to a vicriviroc-containing antiret-
roviral drugs regimen with high-level resistance 
to vicriviroc and another small-molecule CCR5 
antagonist, the susceptibility to inhibition of the 
HGS004 increased [119]. However, an anti-HIV 
synergistic effect was revealed for each group for 
most combinations of CCR5mAbs and small-
molecule CCR5 antagonists, and this syner-
gistic effect was attributed to cobinding in the 
distinct epitopes of the CCR5 receptor [114,121]. 
The synergistic effect was also observed between 
CCR5mAb and enfuvirtide [114,121].
 n Antiphospholipid human mAb
Brown et al. described a murine mAb against 
phosphatidylinositol phosphate that neutralizes 
HIV-1 in PBMC cultures [122]. Recently, Moody 
et al. reported that four human antiphospho-
lipid mAbs (PGN632, P1, IS4 and CL1) inhibit 
HIV-1 R5 primary isolate infection of PBMCs 
with an IC
80
 of less than 0.02 to approximately 
10 µg/ml [123]. The mechanism of HIV inhib-
ition involved stimulation of an innate anti-
HIV-1 response, including the release of soluble 
chemokines, such as MIP-1a and MIP-1b, which 
block HIV-1 entry [123]. These results suggest 
that anti-phospholipid human mAbs could target 
immunotherapy in HIV-infected individuals. 
 n F105, anti-gp 120 human IgG1k mAb
gp120, which is located at the plasma membrane 
of HIV-1-infected cells and on the surface of HIV 
particles, provides an excellent means of discrim-
inating HIV-1-infected host cells from non-
infected cells. It is a viral glycopeptide that plays 
a pivotal role in the HIV-entry process. The bind-
ing of the HIV envelope, gp120, with the CD4 
receptor of the CD4+ T lymphocyte initiates a 
cascade of events that leads to viral entry. gp120 
contains a relatively conserved CD4 binding site 
that offers an accessible epitope for recognition 
by mAbs [124]. F105 is a human IgG1k mAb that 
was derived from a HIV-1-infected individual. It 
binds to a discontinuous epitope overlapping, but 
not entirely congruent, with the CD4 binding 
region of gp120, and competes with soluble CD4 
for gp120 binding. F105 is capable of binding 
antigen expressed on the surface of a wide range 
of HIV-1 laboratory strains and primary isolates, 
thereby neutralizing a subset of these strains. In 
addition, it has been shown to neutralize the IIIB, 
SF2 and MN strain of HIV at concentrations 
readily achievable in humans [124]. In a Phase I 
dose-escalation clinical study, F105, administered 
as a single intravenous injection, demonstrated 
the full anti-gp120 binding activity and was safe, 
nontoxic and well tolerated [125]. 
A recently reported study, using a heavy-chain 
fragment of the mAb F105, fused to protamine 
for delivering siRNA and targeting the viral gag 
mRNA, specifically into HIV-1-infected cells. 
This study demonstrated that HIV production 
in previously infected CD4+ T lymphocytes 
could be suppressed by this modality [126]. In 
addition, the most recent study demonstrated 
the specificity of binding and entry of F105 into 
HIV-infected cells. F105 was rapidly taken up 
into the cell, accumulated in the Golgi appara-
tus and displayed a higher gp120 affinity. F105 
bound exclusively to cells expressing gp120 in 
a co receptor-independent manner and did not 
bind to HIV-uninfected cells. These data fur-
ther support the potential of mAbs as immuno-
therapeutic targeting agents and offer new 
insights into the possibility of F105 as an excel-
lent targeting moiety for the selective delivery of 
antiretroviral drugs or cytotoxic compounds to 
HIV-1-infected cells [127].
 n IgG-reactive antibodies
An immunogen able to drive broadly neutral-
izing antibodies has yet to be identified for HIV 
infection. In healthy individuals, a functional 
immune network contains a wide range of natu-
ral autoantibodies, with T and B lymphocyte 
clones being essential for self-assertion [128]. 
Recent data has demonstrated that broadly and 
potently neutralizing anti-HIV-1 human mAbs 
comprised of B lymphocytes of HIV-1-infected 
individuals have features of natural autoantibod-
ies [129]. Antibodies directed against carbohy-
drate moieties of glycoproteins, including those 
of HIV-1 gp120, are present in normal human 
serum (NHS) [130]. The affinity chromatography-
separated (fractionated) IgG-reactive antibodies 
(anti-IgG antibody) made from NHS, which 
also can react with a gp120 V3 loop derived 
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peptide, prevented human PBMC infection by 
HIV-1 primary isolates, but unfractionated total 
NHS IgG did not neutralize HIV-1 infectiv-
ity [131]. The recent data have demonstrated the 
importance of the natural anti-HIV immune 
response in HIV-infected individuals [132]. 
In addition, a very recent study showed that 
anti-IgG antibodies purified from NHS and 
a GammaBind G Sepharose Flowthrough™ 
(Amersham Biosciences, NJ, USA) fraction for 
the removal of IgM and IgG, which contained 
the IgG
2
 dimers, neutralized HIV-1
BaL
 strain 
with 100% effectiveness at 2 µg/ml concentra-
tion, as well as both HIV-1 X4- and R5-tropic 
primary isolates with an IC
50
 between 0.4 and 
1.8 µg/ml [133]. Therefore, anti-IgG antibodies 
may be useful as a new immunotherapeutic tool 
in HIV-infected individuals.
Immune-modulating drugs
 n Antiviral hyperactivation-limiting 
therapeutics (virostatics)
Antiviral hyperactivation-limiting therapeu-
tics (AV-HALTs) are a newly investigated class 
of antiretroviral drugs. Unlike other classes 
of antiretroviral drugs given to suppress HIV 
replica tion, AV-HALTs are single or combi-
nation drugs designed to reduce the rate of 
viral replication while, at the same time, also 
directly reducing the state of immune-system 
hyper activation that is believed to drive the 
loss of CD4+ T lympho cytes leading to disease 
progression of HIV.
Chronic immune stimulation, owing to per-
sistent HIV replication, induces continuous 
T lymphocyte activation and proliferation of 
both HIV-infected and bystander cells, ulti-
mately resulting in the exhaustion of the immune 
system [134,135]. There is a growing recognition 
that successful long-term therapy of HIV infec-
tion should not only reduce HIV replication, but 
also ultimately limit the chronic hyperactivation 
of the immune system. Therefore, AV-HALTs, 
also called virostatics, are designed to accomplish 
two goals: the reduction of plasma HIV VL and 
the reduction of immune system hyperactivation. 
Virostatics are characterized by the combination 
of a drug directly limiting HIV replication (viro) 
and another drug indirectly inhibiting the HIV 
by reducing cellular proliferation (static).
Antiviral hyperactivation-limiting thera-
peutics have been developed as two forms of 
multi drug combined regimens (first generation) 
or single drugs composed of a single molecule 
(second generation). First-generation AV-HALTs 
accomplish this by combining an antiretroviral 
drug (e.g., didanosine [ddI]) with a cytostatic 
agent (e.g., hydroxyurea [HU]) as a new class of 
drugs [136]. The HU–ddI combination has been 
shown to synergistically limit immune activation 
and control HIV replication by both antiviral 
and cytostatic activities. The mechanism of this 
combined regimen is based on the capacity of 
HU to reduce the synthesis of intracellular com-
ponents required for HIV replication, namely 
deoxyneucleotides (dNTP), in particular, deoxy-
adenosine trisphosphate (dATP, a ddI competi-
tor), by inhibiting ribonucleotide reductase, a 
cell ular enzyme that transforms ribonucleotides 
into dNTP [137]. Therefore, by decreasing the 
availability of the natural substrates (such as 
dNTP), HU increases the relative concentration 
of the NRTI, resulting in increased anti-HIV 
activity. Because the nucleoside analog ddI is the 
precursor of the dATP analog, HU can help to 
reduce the cellular pool of dNTP while ddI ter-
minates DNA synthesis. In addition, because the 
majority of HIV-1 replication occurs in actively 
dividing cells, HU can limit cellular prolifera-
tion, thereby limiting HIV replication in target 
cells (e.g., CD4+ T lymphocytes) [138]. 
The HU–ddI combination regimen has sev-
eral advantages, such as a favorable resistance and 
anti-HIV profiles, the ability to suppress various 
resistant quasispecies and to provide the poten-
tial for durability, because HU targets are not 
viral enzymes (e.g., reverse transcriptases and 
proteases), but are essential cellular proteins. In 
addition, the HU–ddI combination regimen has 
also been shown to compensate for resistance to 
ddI, explaining the long-term anti-HIV efficacy 
observed with this combination [139]. This com-
bination has immune modulating activity and 
reduces viral targets (such as CD4+ T lympho-
cytes), possibly with limited immunosuppres-
sive effects. Regarding the concerns of immu-
nosuppressive effects of HU, several studies have 
demonstrated that HU blocks cellular prolifera-
tion but does not impede cellular activation nor 
diminish recall response [140,141]. In addition, 
suppression of immune activation by cytostatic 
drugs, such as HU, could complement cART. 
Although, upon treatment with HU and ddI, the 
CD4+ T lympho cyte increase is blunted and the 
functionality of the immune system is conserved. 
Although the earlier studies resulted in concerns 
regarding the decrease in CD4+ T lymphocyte 
count, treatment failure and the pancreatic tox-
icity of high-dose HU treatment (1200 mg/
daily) [142], the low-dose HU (600 mg/daily) 
treatment demonstrated better tolerability, rare 
adverse events and greater potency in suppressing 
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HIV replication than high-dose HU treat-
ment [136]. The combination of HU and ddI 
strikes a balance between viral suppression and 
drug-related toxicity and could have a role in 
both delaying cART, by an induction therapy 
that limits viral replication and loss of CD4+ 
T lymphocytes, and substituting cART with 
maintenance therapy. The VS411-C201 study is 
a Phase IIa randomized, double-blind, five-arm, 
dose-finding, multicenter study performed with 
various dosages of VS411, which is the enteri-
cally coated capsule composed of low-dose HU 
and slow-release ddI combination. This study was 
started in 2008 and the results are expected to be 
reported soon.
Mycophenolate mofetil (MMF) selectively 
inhibits the de novo synthesis of guanosine 
nucleotides by competing with inosine mono-
phosphate dehydrogenease; therefore, it would 
be expected to potentate the effects of guanosine 
inhibitors of reverse transcriptase such as abaca-
vir. Cyclosporine (CSA) can suppress T-cell acti-
vation and may have anti-HIV activity through 
the interaction with HIV-1 Gag polyprotein to 
interfere with viral maturation. Therefore, other 
virostatics such as MMF and CSA can theo-
retically have some efficacy in controlling HIV 
and/or reservoirs. However, several small clini-
cal studies with MMF and CSA, combined with 
various antiretroviral drugs, have demonstrated 
conflicting results with regard to VL and CD4+ 
T lymphocyte counts as well as potential adverse 
events, including immune suppression, in spite 
of the promising in vitro results demonstrating 
inhibition of HIV replication [143–147].
 n Minocycline
Minocycline is an antibiotic with immuno-
modulatory and anti-inflammatory activity that 
markedly reduces the expression of monocyte 
chemoattractant protein (MCP)-1, as detected 
in cerebrospinal fluid in the SIV/macaque model 
of HIV-1 infection [148]. Therefore, minocy-
cline, as an immunomodulatory drug, could 
be an effective, low-cost, adjunctive treatment 
to cART.
Szeto et al. recently reported that minocycline 
can attenuate HIV-1 infection and replication by 
suppressing the activation of CD4+ T lympho-
cytes [149]. This study revealed that minocycline 
decreased single-cycle CXCR4-tropic HIV repli-
cation in a dose-dependent manner and decreased 
intracellular viral RNA levels after in vitro infec-
tion of primary human CD4+ T lymphocytes. 
Reactivation of HIV was also decreased in a 
primary CD4+ T lymphocyte-derived model of 
HIV latency and in resting CD4+ T lymphocyte 
reservoirs from HIV-infected patients who had 
undetectable plasma VL with cART. In addi-
tion to these findings, minocycline treatment 
altered T lymphocyte activation and caused 
significant blunting changes in expression of 
activation/proliferation markers and cytokine 
secretion of CD4+ T lymphocytes in response 
to activation [149]. Minocycline may mediate 
anti-HIV activities by altering the cellular envi-
ronment through reduction of the secretion of 
inflammatory cytokines (such as IL-2, IFN-g and 
TNF-a) rather than via direct effects on HIV-1 
replication. Because minocycline may target a 
step downstream of early T lymphocyte activa-
tion events, it may be classified as a new class of 
anticellular anti-HIV drugs. 
In addition, Zink et al. demonstrated that 
minocycline decreases the HIV VL in both 
plasma and cerebrospinal fluid and decreases 
viral RNA in the brain, using the advanced 
SIV/macaque model of HIV-associated neuro-
logic diseases [148]. Minocycline treatment also 
reduced the severity of CNS disease with anti-
HIV activities and anti-inflammatory effects. 
In addition to the inhibitory mechanism on 
p38 mitogen-activated protein kinase activ-
ity cascade, minocycline may suppress HIV-1 
infection by inhibiting HIV-1 integrase [150,151]. 
These findings suggest that minocycline uses 
one additional pathway to inhibit HIV-1 repli-
cation. More active research is required to reveal 
the anti-HIV mechanisms and clinical benefits of 
minocycline. Because minocycline has the advan-
tages of being able to penetrate the blood–brain 
barrier and neuroprotective activity, it could be 
effectively used to prevent and/or treat HAND, 
including asymptomatic neurocognitive impair-
ment. Currently, the efficacy of minocycline in 
reducing neurologic disorder in HIV-infected 
individuals is being analyzed in clinical tri-
als [201]. Several questions must be studied to clar-
ify the clinical benefits of minocycline, such as 
whether normally prescribed doses could achieve 
serum or cellular levels that would be effective 
in suppressing HIV-1 replication in humans, 
and whether it has cross-interactions with other 
antiretroviral drugs.
Nevertheless, because minocycline has a num-
ber of advantages, including the enhanced pene-
tration to tissue, especially brain, low incidence of 
toxicity with long-term administration, and low 
cost, the anti-HIV effects of minocycline, which 
are mediated by altering the cellular environment 
rather than directly targeting virus, suggest that 
it could be an anticellular anti-HIV drug. 
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Programmed death-1 
In the setting of chronic infection, such as HIV, 
the immune regulation function is also able to 
prevent the deleterious effects of unchecked 
immune activation caused by the body’s response 
to the persistent antigen. Our immune system 
has developed various mechanisms to perform 
this regulatory role, one of which is through the 
transmembrane immunoreceptor, programmed 
death-1 (PD-1), which is a negative regulator 
of activated T lymphocytes. The progressive 
loss and exhaustion of T lymphocyte function 
in the setting of various chronic viral infections 
has been associated with the upregulation of 
PD-1 [152–154]. 
 In HIV infection, the level of expression of 
PD-1 on T lymphocytes correlates with decreased 
HIV-specific T lymphocyte function, and PD-1 
expression can be used to predict HIV disease 
progression in that PD-1 level is positively corr-
elated with increases in HIV-specific CD8+ 
T lymphocytes and plasma VL, while negatively 
associated with CD4+ T lymphocyte counts [155]. 
In addition, PD-1 blockade using PD-1 anti-
bodies resulted in the recovery of HIV-induced 
T lymphocyte exhaustion through an increase in 
HIV-specific CD8+ T lymphocyte proliferation 
and cytokine production in vitro [156]. Velu et al. 
recently presented the first in vivo study results 
to demonstrate enhancement of a SIV-specific 
immune response, which is an expansion of SIV-
specific, polyfunctional CD8+ T lymphocyte 
counts and function, through PD-1 blockade, 
using an anti-PD-1 antibody, with nine SIV-
infected macaques [157]. This study also reported 
that the enhanced immunologic response, follow-
ing anti-PD-1 antibody treatment, corresponded 
with significant reductions in plasma VL and 
prolonged survival, as well as good tolerabil-
ity, with no evidence of newly developed auto-
immunity [157]. Anti-PD1 antagonists appear to 
be a novel immunotherapeutic tool in HIV infec-
tion. Recently, the administration of CT-011 (a 
humanized IgG
1
 monoclonal PD-1 antibody) in 
patients with advanced hematologic malignancies 
demonstrated safety and good tolerability [158]. 
However, some issues, including the likeli-
hood of the development of autoimmunity with 
repeated administration of anti-PD1 antagonists, 
the effect of blocking regulatory T lympho-
cytes and the presence of multiple inhibitory 
receptors that coregulate CD8+ T lymphocyte 
exhaustion in chronic viral infection should be 
further evaluated to help ensure a successful out-
come with anti-PD-1 therapy in HIV-infected 
individuals [159,160]. 
Nanotechnology-based approaches 
for immunotherapy
Although the preclinical studies demonstrated 
enhancement of immune responses, most of 
the clinical trials for therapeutic immuniza-
tion have consistently failed to provide clini-
cal improvements in HIV-infected individuals. 
Most of these therapeutic vaccine studies have 
been based on the delivery of the immunogenic 
factors through viruses or ex vivo DCs. The vac-
cine delivery through viral vectors has various 
risks and ex vivo generation and manipulation of 
autologous DCs is a difficult therapeutic strategy 
to utilize widely as it involves very labor intensive, 
complicated procedures with high costs and mul-
tiple pro cedures for product control at different 
sites [161]. Therefore, new approaches, using tar-
geted nanotechnology techniques for delivery of 
immunomodulatory drugs and targeting antigens 
to DCs surface receptors in vivo, could provide 
very important opportunities [3].
Various polymeric systems have been explored 
for in vivo targeting of DCs and delivery of 
small molecules, proteins or DNAs showing 
potential for immunotherapy in HIV infection. 
Polyethylene glycol (PEG)-stabilized polypropy-
lene sulfide (PPS) polymer nanoparticles accu-
mulate in DCs that exist in lymph nodes 
(LNs) [162]. Following interstitial injection of 
PPS nano particles, nanoparticle-containing DCs 
accumulate in the LNs, with levels peaking at 
96 h with 40–50% of DCs and other APCs hav-
ing internalized nanoparticles [162]. In another 
study, nano particles made of poly-d,l-lacticide-
coglycolic acid (PLGA) copolymer demonstrated 
enhanced delivery of antigens to murine bone 
marrow-derived DCs in vitro [163]. More recently, 
a report demonstrated that HIV p24 protein, 
absorbed on the surface of surfactant-free anionic 
poly-d,l-lactide (PLA) nanoparticles, was effi-
ciently taken-up by mouse DCs, resulting in an 
enhanced cellular and mucosal immune response 
in mice [164]. However, the clinical study for these 
nanoparticles has not yet been started.
The most clinically advanced application of 
nanotechnology for immunotherapy of HIV is 
the DermaVir Patch that reached Phase II clinical 
trials [201]. DermaVir, a topical DC-based HIV 
DNA plasmid vaccine, is a targeted nanoparticle 
system based on mannose-targeted polyethyleni-
mine polymer, glucose and HIV antigen-coding 
plasmid DNA formulated into nanoparticles 
(~100 nm) and administered under a topical 
patch between the epidermal and dermal skin lay-
ers, where large numbers of Langerhans cells and 
dermal DCs are found [165–167]. The nanoparticles 
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are delivered to epidermal Langerhans cells that 
trap the nanoparticles and mature to become 
highly immunogenic on their way to the LNs. 
Mature DCs, containing the nanoparticles, pres-
ent antigens to T lymphocytes inducing cellular 
immunity. DermaVir is immunogenic and safe 
in SIV-infected rhesus macaques, and a novel 
formulation, which includes an IL-15 plasmid 
intended to enhance HIV-specific memory 
T-cell production, is being prepared for test-
ing [168,169]. Preclinical studies and Phase I clini-
cal trials demonstrated safety and tolerability of 
the DermaVir patch, which led the progression 
to Phase II clinical trials to assess the safety, 
tolerability, immunogenecity and antiretro viral 
activity of the DermaVir patch (LC002) in 
treatment-naive, HIV-1-infected individuals and 
to investigate the effect of therapeutic immuni-
zation on the quantity of HIV-specific T-cell 
precursors during cART followed by STI as the 
antiretroviral-sparing concept in HIV-infected 
patients currently under cART [201]. This is the 
first nanotechnology-based immunotherapy for 
HIV that has reached clinical studies and further 
work in this area is encouraged. 
Radioimmunotherapy
Some scientists at the Albert Einstein College 
of Medicine of Yeshiva University (NY, USA) 
have piggybacked antibodies onto radioac-
tive payloads in order to deliver radiation that 
selectively targets and destroys HIV-infected 
cells. It is important that the development of a 
delivery system of microbicidal radiation uses 
highly specific microbe-targeting mAbs. By 
attaching radio active material to a particular 
antibody, radiation can be targeted at specific 
cells that express the corresponding antigen, 
minimizing collateral damage to other tissues. 
This experimental treatment, termed radioim-
munotherapy (RIT), could be used to treat HIV 
infection. This new moda lity, which targets and 
kills HIV-1-infected cells when combined with 
cART, could have a major impact on the treat-
ment of acute HIV infection through elimina-
tion of persistent reservoirs of HIV-infected 
cells. The Albert Einstein team examined the 
efficacy of RIT for treatment of HIV infection 
in vivo with a HIV envelope- specific human 
anti-gp41 mAb 246-D radiolabeled with 213Bi 
or 188Re. Unlike other HIV-related glycoproteins, 
gp41 antigen usually is not shed into the blood-
stream, which would lead many of radioactive-
labeled antibodies to miss their target. Human 
PBMCs, infected with HIV-1
JR-CSF
 were injected 
into the spleens of SCID mice and the mice were 
treated intraperitoneally with radiolabeled mAbs 
1 h later. Treatment of mice with 188Re-labeled 
mAb 246-D, administered either before or after 
intrasplenic injection, dramatically reduced the 
number of HIV-1-infected cells. Similar results 
were obtained after the treatment of mice with 
213Bi-246-D. However, 188Re-246-D was more 
effective in vivo than 213Bi-246-D. Consequently, 
their studies showed that RIT could effectively 
target and kill HIV-1-infected human PBMCs 
in vivo [170]. However, when using a RIT in HIV-
infected patients, we must always be concerned 
about the short-term (e.g., hematologic toxicity) 
or long-term adverse effects (e.g., neoplasm). In 
addition, the appli cation of RIT to HIV infection 
will require optimization of the dose to ascertain 
and minimize toxic effects.
Future perspective
Table 2 summarizes the currently ongoing clinical 
studies in the field of immunotherapy of HIV 
infection [201]. 
The recent, large SILCAART and ESPRIT 
studies yielded disappointing results for IL-2, 
which has been the most promising immuno-
therapeutic tool for HIV infection. Therefore, 
the modification of current immunotherapeutic 
approaches for HIV should be considered. The 
results of in vivo studies, including human tri-
als and animal models, or in vitro studies that 
promise immune restoration in HIV infection 
must also demonstrate clear improvements of 
clinical outcomes, such as decreases in mortality 
and/or morbidities caused by HIV infection. The 
SILCAAT and ESPRIT studies finally proved 
that IL-2 is too toxic for immunotherapeutic use 
and focused attention on IL-7. Most recently, 
IL-7 is one of the new candidates of immuno-
therapy in HIV infection. Although much fewer 
clinical data are currently available for IL-7, it 
seems that IL-7 is superior to IL-2 in terms of 
safety and tolerability. Furthermore, IL-21, 
which has been the most actively researched 
cytokine immunotherapy until now, could be 
an important target in HIV infection. 
One possible strategy to circumvent the prob-
lem of the induction of anti-HIV-1 antibodies is 
to search for antibodies with novel specifications 
that can inhibit HIV-1 infectivity and that could 
be potentially used as a vaccine strategy. Synthetic 
peptide immunogens are amenable to modifica-
tions that may improve immuno genicity and 
reactivity to HIV infection. Peptide immuno gens 
providing beneficial effects when used in thera-
peutic immunization programs may provide the 
basis for future HIV vaccines [61]. A clinical study 
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that will evaluate the therapeutic value of puls-
ing overlapping HIV peptides onto PBMCs or 
whole blood in humans is anticipated, owing to 
the promising results of previous studies in non-
human primates [171]. New delivery methods for 
therapeutic vaccines, for example vaccines that 
will be administered into the intradermal area 
by electroporation, and new various immuno-
modulators that will be used as adjuvants to vac-
cine therapies, are currently being developed and 
assessed for use as immunorestoration modalities 
to combat HIV infection.
A neutralizing antibody against HIV-1 is one 
of the essential elements of the immunothera-
peutic restoration in HIV infection. However, 
primary isolates of HIV-1 are relatively resistant 
to neutralization compared with variants selected 
for growth in cell lines [172]. With regard to the 
role of neutralizing antibody responses in HIV 
infection, it remains important to determine 
whether high-titered and cross-reactive neu-
tralizing antibodies will be produced by active 
immunization with a novel viral antigen.
Among the immunotherapies using mAb, 
novel CCR5 mAbs have been yielding the 
most hopeful results. CCR5 mAbs have several 
important advantages over existing therapies in 
terms of infrequent (e.g., single) dosing, favor-
able safety, limited drug–drug interactions, syn-
ergistic effects with other antiretroviral drugs, 
such as small-molecule CCR5 antagonists or 
enfuvirtide, and no cross-resistance with small-
molecule CCR5 antagonists. Further promising 
results are warran ted for CCR5 mAb, especially 
in combination therapy with small-molecule 
CCR5 antagonists.
In addition, ibalizumab could be developed 
as an important novel therapeutic drug in HIV 
immunotherapy because its mechanisms of 
action allow anti-HIV activity, regardless of 
chemokine receptor tropism, and it is likely that 
the cross-resistance with other classes of antiret-
roviral drugs is relatively low. However, further, 
larger studies in various clinical settings, includ-
ing treatment-experienced patients or combina-
tion with standard cART, must be performed 
to expand its clinical usefulness. In addition, 
the most recent clinical studies have not shown 
sustained anti-HIV activity, despite continued 
treatment [88]. Furthermore, because emerg-
ing resistance to ibalizumab was manifest by 
reduced maximal percentage inhibition [88], the 
Table 2. Ongoing clinical immunotherapeutic trials in HIV-infected individuals.
Treatment drugs 
and modalities
Phase Study designs and objects Study 
participants
Comments
Ibalizumab IIb Randomized, double-blinded, 48-week, multicenter, 
dose–response study of ibalizumab (800 mg every 
2 weeks vs 2000 mg every 4 weeks) plus an OBR 
Treatment-
experienced 
patients 
TMB-202 study
KD-247 I To evaluate the safety, tolerability and 
pharmacokinetics of KD-247
Asymptomatic, 
treatment-naive 
individuals 
–
UB-421 antibody I Open-label, single-dose, dose-escalation study to 
evaluate the safety and pharmacokinetics of 
UB-421 antibody
Asymptomatic, 
HIV-1-infected 
adults
UB-421 is the antibody targeting 
the HIV-1 receptor on the CD4 
molecule (domain 1) of 
T lymphocytes and monocytes. 
The neutralizing activity of 
UB-421 blocks HIV-1 from binding 
to its receptor on CD4+ cells
IL-7 I Randomized, placebo-controlled, double-blind study 
evaluating the safety of subcutaneous, single-dose, 
recombinant human IL-7 
HIV-1-infected 
subjects who are 
receiving ART
–
TNX-355 II Multicenter, randomized, double-blind, placebo-
controlled, three-arm study of the anti-CD4 
monoclonal antibody TNX-355 with OBR 
Treatment-
experienced 
patients
–
Lymphocyte 
infusion
Immunologic and virologic response in HIV-infected 
HLA-B*57 progressors after infusion of lymphocytes 
from HIV-infected HLA-B*57 ‘elite’ long-term 
nonprogressors
Patients failing 
ART
To evaluate the effect of giving 
HLA-B*57 to white blood cells 
from an individual with a 
controlled HIV infection to an 
individual who cannot control HIV 
infection, as a form of HIV 
treatment (apheresis)
ART: Antiretroviral therapy; OBR: Optimized background regimen.  
Data from [201].
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development of resistance to ibalizumab must be 
overcome. While the Phase IIa study is complete, 
a 24-week Phase IIb dose-comparison study for 
ibalizumab is still in progress [201].
Virostatic action may be a novel multipronged 
approach for attacking HIV. It has primarily 
been studied in patients with advanced HIV 
disease as the salvage therapy or as components 
of trials involving STI. However, virostatics may 
have a role either in primary treatment or as adju-
vant to existing cART. Several critical problems 
regarding immune-based therapies remain to be 
answered, including the most proper clinical set-
tings for therapy, the optimum administration 
schedules (dosing, duration and intervals) and 
ideal antiretroviral drug combination. Additional 
cytostatic small molecules, which can result in 
cell-cycle arrest (e.g., rapamycin, roscovitine and 
resveratol, among others), could be candidates 
for virostatics therapy in HIV infection [173,174]. 
A recent small, randomized, double-blind, pla-
cebo-controlled pilot study demonstrated that 
leflunomide, which was approved by the US 
FDA for the treatment of rheumatoid arthritis, 
was effective in reducing immune activation in 
chronic HIV-infected individuals and was well 
tolerated with low-grade adverse events [175].
The immunomodulatory effects of minocy-
cline promise to reduce the damaging immu-
nopathogenesis resulting from HIV infection, 
particularly in tissues such as the brain. The 
immunomodulatory and anti-HIV effects of 
minocycline strongly suggest that it would be 
effective as a novel maintenance anti-HIV agent 
with cART. Minocycline could prevent reacti-
vation of HIV from the CD4+ T lymphocyte 
latent reservoir and provide therapeutic immu-
nomodulation by dampening chronic immune 
activation and inflammatory processes that con-
tribute to pathogenesis. Besides virostatics and 
minocycline, oleanolic acid, desferrioxamine and 
CpG oligodeoxyneucleotides are other possible 
immunomodulatory drugs for the treatment of 
HIV infection.
Executive summary
  Alternative adjunctive immunotherapeutic strategies, which complement combined active antiretroviral therapy (cART), remain active 
research foci. 
  The development of new immunotherapic strategies for the treatment of HIV infection is critical, especially for immunologic 
nonresponders to cART and for use in supportive adjuvants for structured treatment interruption of antiretroviral therapy for 
antiretroviral drug conservation.
  The results of two recent, large studies, The Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous 
Recombinant, Human IL-2 in HIV-infected Patients with Low CD4 Counts Under Active Antiretroviral Therapy (SILCAART) and The 
Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT), demonstrated that IL-2, combined with antiretroviral 
therapy, did not result in clinical benefits when the development of opportunistic disease or death from any cause were considered as 
outcome indicators.
  The SILCAAT and ESPRIT studies finally proved that IL-2 is too toxic for immunotherapeutic use, and focused attention on IL-7. Most 
recently, IL-7 has been a new candidate for immunotherapy in HIV infection.
  HIV DNA therapeutic vaccines, including immunomodulators of various cytokines or dendritic cells, are being actively evaluated. 
  A neutralizing monoclonal antibody (mAb) against HIV-1, such as ibalizumab, KD-247 or CCR5mAb, is an essential element in 
immunotherapeutic restoration with HIV infection.
  The emerging clinical and laboratory data support the view that CCR5 mAb offers several potential advantages over existing cART in 
terms of potency, tolerability, dosing frequency and other factors.
  Immune-modulating drugs, including antiviral hyperactivation-limiting therapeutics and minocycline, are promising drugs for 
HIV immunotherapy.
  Nanoimmunotherapy, or nanotechnology-based vaccines, are another major treatment option requiring further clinical studies. The 
results from the Phase II DermaVir patch clinical trials will be available soon. 
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